Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.58 |
| ▸ | JAK1 | P23458 | 11/20 | 0.58 |
| ▸ | JAK2 | O60674 | 6/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062093 | 1.00 | JAK3 (0.58) | JAK3JAK1JAK2ROCK2ROCK1 | |
| SCHEMBL15390126 | 0.86 | JAK1 (0.56) | JAK3JAK1JAK2ROCK2ROCK1 | |
| SCHEMBL15389489 | 0.81 | JAK2 (0.51) | JAK3JAK1JAK2ROCK2ROCK1 | |
| SCHEMBL1120755 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL19757378 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL18134011 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL18124371 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL11949307 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL28412373 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL29216398 | 0.81 | JAK3 (0.72) | JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671882-B1 | pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9879010-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879010-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-9580419-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580419-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150315185-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2015-11-05 | — | — | US | disclosed |
| US-9090611-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| EP-1828181-B1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2671882-A1 | pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | Incyte Corporation (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130296299-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8445488-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120014989-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-01-19 | — | — | US | disclosed |
| US-8053433-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | Ineyte Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110086835-A1 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-04-14 | — | — | US | disclosed |
| US-7335667-B2 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1828181-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | INCYTE CORPORATION | 2006-08-17 | — | — | US | disclosed |
| WO-2006069080-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086835-A1 | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
| US-20170349579-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-B]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | JAK1, ZAP70, LCK | JAK3 4/4885JAK1 1/4885JAK2 27/4885 |
| US-20130296299-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
| US-20150315185-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
| US-20120014989-A1 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK1 2/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.